Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 6/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.44 |
| ▸ | RELA | Q04206 | 6/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 4/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16599713 | 0.79 | NFKB1 (0.39) | NFKB1NFKB2RELANLRP3 | |
| SCHEMBL16614389 | 0.79 | NFKB1 (0.41) | NFKB1NFKB2RELAGAANLRP3 | |
| SCHEMBL2663976 | 0.77 | ITGB1 (0.41) | NFKB1NFKB2RELANLRP3 | |
| SCHEMBL18187850 | 0.77 | NFKB1 (0.40) | NFKB1NFKB2RELANLRP3 | |
| SCHEMBL16614295 | 0.77 | NFKB1 (0.40) | NFKB1NFKB2RELANLRP3 | |
| SCHEMBL20748348 | 0.76 | BRD4 (0.35) | BRD4MIFHDAC6GAAKMT2A | |
| SCHEMBL18194639 | 0.75 | NFKB1 (0.41) | NFKB1NFKB2RELANLRP3 | |
| SCHEMBL17189143 | 0.73 | NLRP3 (0.57) | NFKB1NFKB2RELALMNANLRP3 | |
| SCHEMBL13740156 | 0.72 | BRD4 (0.34) | BRD4MIFHDAC6GAALMNA | |
| SCHEMBL20809859 | 0.71 | BRD4 (0.33) | BRD4MIFHDAC6GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318862-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | WILLIAM MARSH RICE UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318862-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | WILLIAM MARSH RICE UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318862-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | WILLIAM MARSH RICE UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015048268-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | WILLIAM MARSH RICE UNIVERSITY (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318862-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | DGKZ, DGKG, DNAJA3 | NFKB1 1106/4885NFKB2 787/4885RELA 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.